Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy

Anticancer Res. 2019 Sep;39(9):5115-5122. doi: 10.21873/anticanres.13706.

Abstract

Background/aim: Although various prognostic indices for follicular lymphoma (FL) have been proposed, they are designed specifically for patients requiring immediate therapy. We aimed to develop a new simple prognostic tool applicable for all patients with FL at diagnosis.

Materials and methods: We retrospectively analyzed various clinical, pathological, and laboratory data, including soluble interleukin-2 receptor (sIL2R), from 140 patients with FL from two centers for their impact on prognosis. This study analyzed the impact of soluble interleukin-2 receptor (sIL2R) in order to develop a new simple prognostic tool applicable for all patients with FL at diagnosis.

Results: The initial management of these patients was watchful waiting (n=48) or immediate treatment (n=92). Event-free survival at 24 months predicted overall survival. When categorized into three groups according to the sIL2R levels at diagnosis, a very high sIL2R level identified about 20% of patients with a distinctively worse survival compared to the others.

Conclusion: sIL2R is a very effective biomarker that can be easily applied in routine practice to predict survival for all patients with FL at diagnosis irrespective of initial management approach.

Keywords: Soluble interleukin-2 receptor; follicular lymphoma; prognostic factor.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers
  • Biomarkers, Tumor*
  • Disease Management
  • Female
  • Humans
  • Lymphoma, Follicular / blood*
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / mortality*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Receptors, Interleukin-2 / blood*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers
  • Biomarkers, Tumor
  • Receptors, Interleukin-2